Genome Sequencing and Analysis of the Tasmanian Devil and Its Transmissible Cancer

Elizabeth P. Murchison(Wellcome Sanger Institute), Ole Schulz-Trieglaff(Illumina (United Kingdom)), Zemin Ning(Wellcome Sanger Institute), Ludmil B. Alexandrov(Wellcome Sanger Institute), Markus Bauer(Illumina (United Kingdom)), Beiyuan Fu(Wellcome Sanger Institute), Matthew M. Hims(Illumina (United Kingdom)), Zhihao Ding(Wellcome Sanger Institute), Sergii Ivakhno(Illumina (United Kingdom)), Caitlin M. Stewart(Wellcome Sanger Institute), Bee Ling Ng(Wellcome Sanger Institute), Wendy S.W. Wong(Illumina (United Kingdom)), Bronwen Aken(Wellcome Sanger Institute), Simon White(Wellcome Sanger Institute), Amber E. Alsop(Australian National University), Jennifer Becq(Illumina (United Kingdom)), Graham R. Bignell(Wellcome Sanger Institute), R. Keira Cheetham(Illumina (United Kingdom)), William Cheng(Wellcome Sanger Institute), Thomas R. Connor(Wellcome Sanger Institute), Anthony J. Cox(Illumina (United Kingdom)), Zhiping Feng(The University of Melbourne), Yong Gu(Wellcome Sanger Institute), Russell Grocock(Illumina (United Kingdom)), Simon R. Harris(Wellcome Sanger Institute), Irina Khrebtukova(Illumina (United States)), Zoya Kingsbury(Illumina (United Kingdom)), Mark Kowarsky(Walter and Eliza Hall Institute of Medical Research), Alexandre Kreiss(University of Tasmania), Shujun Luo(Illumina (United States)), John Marshall(Wellcome Sanger Institute), David J. McBride(Wellcome Sanger Institute), Lisa Murray(Illumina (United Kingdom)), Anne‐Maree Pearse, Keiran Raine(Wellcome Sanger Institute), Isabelle Rasolonjatovo(Illumina (United Kingdom)), Richard J. Shaw(Illumina (United Kingdom)), Philip Tedder(Illumina (United Kingdom)), Carolyn Tregidgo(Illumina (United Kingdom)), Albert J. Vilella(European Bioinformatics Institute), David C. Wedge(Wellcome Sanger Institute), GM Woods(University of Tasmania), Niall Gormley(Illumina (United Kingdom)), Sean Humphray(Illumina (United Kingdom)), Gary P. Schroth(Illumina (United States)), Geoff Smith(Illumina (United Kingdom)), Kevin P. Hall(Illumina (United Kingdom)), Stephen M. J. Searle(Wellcome Sanger Institute), Nigel P. Carter(Wellcome Sanger Institute), Anthony T. Papenfuss(The University of Melbourne), P. Andrew Futreal(Wellcome Sanger Institute), Peter J. Campbell(Wellcome Sanger Institute), Fengtang Yang(Wellcome Sanger Institute), David Bentley(Illumina (United Kingdom)), Dirk J. Evers(Illumina (United Kingdom)), Michael R. Stratton(Wellcome Sanger Institute)
Cell
February 1, 2012
Cited by 345Open Access
Full Text

Abstract

The Tasmanian devil (Sarcophilus harrisii), the largest marsupial carnivore, is endangered due to a transmissible facial cancer spread by direct transfer of living cancer cells through biting. Here we describe the sequencing, assembly, and annotation of the Tasmanian devil genome and whole-genome sequences for two geographically distant subclones of the cancer. Genomic analysis suggests that the cancer first arose from a female Tasmanian devil and that the clone has subsequently genetically diverged during its spread across Tasmania. The devil cancer genome contains more than 17,000 somatic base substitution mutations and bears the imprint of a distinct mutational process. Genotyping of somatic mutations in 104 geographically and temporally distributed Tasmanian devil tumors reveals the pattern of evolution and spread of this parasitic clonal lineage, with evidence of a selective sweep in one geographical area and persistence of parallel lineages in other populations.


Related Papers

No related papers found

Powered by citation graph analysis